+关注
Charis4455
暂无个人介绍
IP属地：未知
8
关注
1
粉丝
0
主题
0
勋章
主贴
热门
Charis4455
2021-12-01
Huatz
Merck shares jumped 5.3% in premarket trading
Charis4455
2021-11-13
Cool
抱歉，原内容已删除
Charis4455
2021-12-15
:(
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582016082149562","uuid":"3582016082149562","gmtCreate":1618922380873,"gmtModify":1623984995436,"name":"Charis4455","pinyin":"charis4455","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":8,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"60.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":607649897,"gmtCreate":1639536362062,"gmtModify":1639536362062,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607649897","repostId":"1180160205","repostType":4,"repost":{"id":"1180160205","kind":"news","pubTimestamp":1639534172,"share":"https://www.laohu8.com/m/news/1180160205?lang=&edition=full","pubTime":"2021-12-15 10:09","market":"us","language":"en","title":"Upstart Shares Have Plunged, But Stay Away for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1180160205","media":"InvestorPlace","summary":"Even after crashing, UPST stock remains risky","content":"<p><b>Upstart</b> (NASDAQ:<b><u>UPST</u></b>) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.</p>\n<p>You probably wouldn’t realize that if you’ve just tuned into the Upstart story, however. While UPST is up huge on the year, the gains have shrunk dramatically from where they were back in October. At that point, the stock had briefly hit $400 as speculative fervor peaked.</p>\n<p>The top soon came following an embarrassing interview on<i>CNBC</i>. The business channel had on stock trader Mark Minervini to discuss UPST stock and Minervini talked up the company’s strong technicals and momentum. However, when the <i>CNBC</i> host asked Minervini to explain Upstart’s business model, he froze up. Seemingly unable to answer, Minervini blamed audio issues and the interview abruptly ended.</p>\n<p>That moment went viral and the UPST stock price soon started to crash. It seems a lot of people, like Minervini, appreciated Upstart primarily because of its strong price performance rather than the company’s actual business. With the momentum in the stock long gone, however, is it time to buy in during this correction?</p>\n<p><b>UPST Stock: Rapid But Slowing Growth</b></p>\n<p>At first glance, Upstart’s third-quarter earnings report didn’t look too bad. The company beat estimates on both the top and bottom line. In particular, the earnings figure was substantially ahead of expectations. Based on that, you might have thought Upstart would rally on the results, or at least hold its ground. Instead, UPST stock immediately plunged 20% upon the Q3 release.</p>\n<p>What went wrong? For one thing, investors had their expectations in the stratosphere. Analysts may have had more conservative numbers, but quick money traders were expecting massive growth in Q3 after Q2’s blowout earnings. Instead, Q3 was only moderately ahead of expectations.</p>\n<p>Specifically, Upstart’s growth rate showed the issues. For the quarter, revenue growth slowed to 18% sequentially versus 60% in Q2. That’s a massive decline. And that came even as some analysts have become concerned that Upstart may be lowering loan quality standards to attract more business. Adding to that point, while the company grew revenues sequentially, the contribution margin actually declined slightly in Q3 versus Q2.</p>\n<p>Long story short, Upstart’s incredible growth phase appears to be drawing to a close. Meanwhile, shares are trading at 100 times this year’s earnings and a projected 77 times forward earnings, according to<i>Seeking Alpha</i>. That’s far too high for a company with rapidly slowing revenue and earnings growth. On top of that, add the fact that it faces substantial cyclical concerns if and when the economy turns downward once again.</p>\n<p>UPST stock completed its initial public offering (IPO) at $20 per share just a year ago. It’s no surprise that the stock is having trouble supporting a price 10 times that high just a year later. Momentum traders got way over their skis on this one.</p>\n<p><b>Analysts Also Worry About Valuation</b></p>\n<p>I’m hardly the only person that’s concerned about Upstart’s valuation, too. For example, Morgan Stanley initiated coverage of Upstart shares last week with a neutral rating.</p>\n<p>Morgan Stanley’s James Faucette did credit the company for its rapid growth. However, Faucette also warned that it has benefitted from unusually favorable credit conditions among other tailwinds. The analyst is monitoring Upstart for incremental changes to the growth story.</p>\n<p>In the meantime, it’s not exactly encouraging that Faucette assigned UPST stock a neutral rating on shares with the stock already back under $200. Just because this name hit $400 before doesn’t necessarily mean it’s a bargain below $200 per share.</p>\n<p><b>The Verdict on Upstart</b></p>\n<p>The last time I covered Upstart, I took an unequivocally negative view, warning that it was “overvalued and set to crash.”Indeed, the stock has plunged from $300 to below $160 since that article’s publication. That wasn’t too complicated of a call — there was absolutely no way to justify a valuation anywhere near that level.</p>\n<p>However, the investment case now is a little more nuanced with the stock down a quick 50%. At this point, shares are oversold — rather than overbought — on a short-term basis. To some extent, UPST stock has gotten hit with tax loss and momentum-based selling as people that bought at $300 and above sell out of shares to move their capital elsewhere.</p>\n<p>So, would it be surprising if UPST stock bounces once the calendar flips into 2022? Not at all. Over the longer-term, though, Upstart remains seriously overvalued compared to its medium-term business prospects. The company will need to expand into more lending verticals — without letting credit quality slide — if it’s going to support a triple-digit price going forward.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstart Shares Have Plunged, But Stay Away for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstart Shares Have Plunged, But Stay Away for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 10:09 GMT+8 <a href=https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Upstart (NASDAQ:UPST) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.\nYou...</p>\n\n<a href=\"https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc."},"source_url":"https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180160205","content_text":"Upstart (NASDAQ:UPST) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.\nYou probably wouldn’t realize that if you’ve just tuned into the Upstart story, however. While UPST is up huge on the year, the gains have shrunk dramatically from where they were back in October. At that point, the stock had briefly hit $400 as speculative fervor peaked.\nThe top soon came following an embarrassing interview onCNBC. The business channel had on stock trader Mark Minervini to discuss UPST stock and Minervini talked up the company’s strong technicals and momentum. However, when the CNBC host asked Minervini to explain Upstart’s business model, he froze up. Seemingly unable to answer, Minervini blamed audio issues and the interview abruptly ended.\nThat moment went viral and the UPST stock price soon started to crash. It seems a lot of people, like Minervini, appreciated Upstart primarily because of its strong price performance rather than the company’s actual business. With the momentum in the stock long gone, however, is it time to buy in during this correction?\nUPST Stock: Rapid But Slowing Growth\nAt first glance, Upstart’s third-quarter earnings report didn’t look too bad. The company beat estimates on both the top and bottom line. In particular, the earnings figure was substantially ahead of expectations. Based on that, you might have thought Upstart would rally on the results, or at least hold its ground. Instead, UPST stock immediately plunged 20% upon the Q3 release.\nWhat went wrong? For one thing, investors had their expectations in the stratosphere. Analysts may have had more conservative numbers, but quick money traders were expecting massive growth in Q3 after Q2’s blowout earnings. Instead, Q3 was only moderately ahead of expectations.\nSpecifically, Upstart’s growth rate showed the issues. For the quarter, revenue growth slowed to 18% sequentially versus 60% in Q2. That’s a massive decline. And that came even as some analysts have become concerned that Upstart may be lowering loan quality standards to attract more business. Adding to that point, while the company grew revenues sequentially, the contribution margin actually declined slightly in Q3 versus Q2.\nLong story short, Upstart’s incredible growth phase appears to be drawing to a close. Meanwhile, shares are trading at 100 times this year’s earnings and a projected 77 times forward earnings, according toSeeking Alpha. That’s far too high for a company with rapidly slowing revenue and earnings growth. On top of that, add the fact that it faces substantial cyclical concerns if and when the economy turns downward once again.\nUPST stock completed its initial public offering (IPO) at $20 per share just a year ago. It’s no surprise that the stock is having trouble supporting a price 10 times that high just a year later. Momentum traders got way over their skis on this one.\nAnalysts Also Worry About Valuation\nI’m hardly the only person that’s concerned about Upstart’s valuation, too. For example, Morgan Stanley initiated coverage of Upstart shares last week with a neutral rating.\nMorgan Stanley’s James Faucette did credit the company for its rapid growth. However, Faucette also warned that it has benefitted from unusually favorable credit conditions among other tailwinds. The analyst is monitoring Upstart for incremental changes to the growth story.\nIn the meantime, it’s not exactly encouraging that Faucette assigned UPST stock a neutral rating on shares with the stock already back under $200. Just because this name hit $400 before doesn’t necessarily mean it’s a bargain below $200 per share.\nThe Verdict on Upstart\nThe last time I covered Upstart, I took an unequivocally negative view, warning that it was “overvalued and set to crash.”Indeed, the stock has plunged from $300 to below $160 since that article’s publication. That wasn’t too complicated of a call — there was absolutely no way to justify a valuation anywhere near that level.\nHowever, the investment case now is a little more nuanced with the stock down a quick 50%. At this point, shares are oversold — rather than overbought — on a short-term basis. To some extent, UPST stock has gotten hit with tax loss and momentum-based selling as people that bought at $300 and above sell out of shares to move their capital elsewhere.\nSo, would it be surprising if UPST stock bounces once the calendar flips into 2022? Not at all. Over the longer-term, though, Upstart remains seriously overvalued compared to its medium-term business prospects. The company will need to expand into more lending verticals — without letting credit quality slide — if it’s going to support a triple-digit price going forward.","news_type":1},"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603919337,"gmtCreate":1638350710918,"gmtModify":1638350710990,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Huatz ","listText":"Huatz ","text":"Huatz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603919337","repostId":"1116877933","repostType":2,"repost":{"id":"1116877933","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638350081,"share":"https://www.laohu8.com/m/news/1116877933?lang=&edition=full","pubTime":"2021-12-01 17:14","market":"us","language":"en","title":"Merck shares jumped 5.3% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1116877933","media":"Tiger Newspress","summary":"Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close","content":"<p>Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.</p>\n<p><img src=\"https://static.tigerbbs.com/52b0f147fff1ac74d32cd5d5643fe2b3\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>The Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>The company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.</p>\n<p>Members of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.</p>\n<p>\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"</p>\n<p>Some Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.</p>\n<p>\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.</p>\n<p>Of the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.</p>\n<p>The monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.</p>\n<p>Molnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.</p>\n<p>Wall Street's interest in Merck's pill began to wane in November when Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.</p>\n<p>Then, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.</p>\n<p>\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.</p>\n<p>Analysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.</p>\n<p>Citi on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.</p>\n<p>Merck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.</p>\n<p>The Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.</p>\n<p>Molnupiravir has already been authorized for use in the U.K.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck shares jumped 5.3% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck shares jumped 5.3% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.</p>\n<p><img src=\"https://static.tigerbbs.com/52b0f147fff1ac74d32cd5d5643fe2b3\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>The Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>The company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.</p>\n<p>Members of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.</p>\n<p>\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"</p>\n<p>Some Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.</p>\n<p>\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.</p>\n<p>Of the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.</p>\n<p>The monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.</p>\n<p>Molnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.</p>\n<p>Wall Street's interest in Merck's pill began to wane in November when Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.</p>\n<p>Then, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.</p>\n<p>\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.</p>\n<p>Analysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.</p>\n<p>Citi on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.</p>\n<p>Merck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.</p>\n<p>The Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.</p>\n<p>Molnupiravir has already been authorized for use in the U.K.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116877933","content_text":"Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.\n\nThe Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.\nThe company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.\nThe FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.\nIf molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.\nMembers of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.\n\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"\nSome Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.\n\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.\nOf the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.\nThe monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.\nMolnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.\nWall Street's interest in Merck's pill began to wane in November when Pfizer Inc. $(PFE)$ produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.\nThen, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.\n\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.\nAnalysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.\nCiti on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.\nMerck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.\nThe Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.\nMolnupiravir has already been authorized for use in the U.K.","news_type":1},"isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879574401,"gmtCreate":1636758992535,"gmtModify":1636758992535,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879574401","repostId":"1163118124","repostType":4,"repost":{"id":"1163118124","kind":"news","pubTimestamp":1636726239,"share":"https://www.laohu8.com/m/news/1163118124?lang=&edition=full","pubTime":"2021-11-12 22:10","market":"us","language":"en","title":"Tesla: $1 Trillion Of Speculation","url":"https://stock-news.laohu8.com/highlight/detail?id=1163118124","media":"Forbes","summary":"Tesla’s market cap surpassed the trillion-dollar mark, driven by a post-earnings rally that got a boost from the announcement of a 100,000-vehicle order from Hertz , which might not even happen.Even if it does come to pass, the Hertz order is a drop in the bucket of growth expectations baked into Tesla’s valuation. Tesla needs 155 Hertz-sized orders to justify the revenue expectations in its stock price. Put another way, the $1.2 trillion valuation implies Tesla owns 60%+ of the entire global p","content":"<p>Tesla’s (TSLA) market cap surpassed the trillion-dollar mark, driven by a post-earnings rally that got a boost from the announcement of a 100,000-vehicle order from Hertz (HTZ), which might not even happen.</p>\n<p>Even if it does come to pass, the Hertz order is a drop in the bucket of growth expectations baked into Tesla’s valuation. Tesla needs 155 Hertz-sized orders to justify the revenue expectations in its stock price. Put another way, the $1.2 trillion valuation implies Tesla owns 60%+ of the entire global passenger EV market and becomes more profitable than Apple (AAPL) by 2030.</p>\n<p>This report provides objective perspective on how outrageously high the valuation of Tesla stock is and the clear impracticality of the company meeting the expectations baked into its valuation.</p>\n<p><b>Tesla’s Valuation vs. Competitors Makes No Sense</b></p>\n<p>Tesla’s market cap is now greater than the next 10 largest (ranked by market cap) auto manufacturers combined.</p>\n<p><b>Figure 1: Tesla’s Market Cap Vs. Competitors</b></p>\n<p><img src=\"https://static.tigerbbs.com/fb58977e39c2d0ce868e80de26d098d9\" tg-width=\"925\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>This valuation comes despite Tesla selling less than 1/50th of the vehicles than the combined total sold by the next 10 largest automakers over the trailing twelve months ended the first half of 2021. See Figure 2.</p>\n<p>I cannot conceive of a straight-faced argument for the disconnect between Tesla’s valuation and its vehicle sales compared to its competitors.</p>\n<p><b>Figure 2: Tesla’s Car Sales Vs. Competitors</b></p>\n<p><img src=\"https://static.tigerbbs.com/7fe8de12677dc13fe01f38fbafdcab27\" tg-width=\"946\" tg-height=\"397\" referrerpolicy=\"no-referrer\">* Stellantis sales estimated as Fiat Chrysler and PSA Group’s 2H20 sales and Stellantis’ 1H21 sales. Stellantis was formed as a merger between the two in January 2021.</p>\n<p><b>Is the Hertz Deal Really Worth $100 Billion+ in Market Cap?</b></p>\n<p>Even if Hertz eventually agrees to buy 100,000 Tesla Model 3s, I do not think it is worth the $100 billion in market cap, or $1 million per vehicle, that we saw investors give Tesla’s market cap after the Hertz deal made headlines. Even Elon Musk questioned the surge in share price, noting that the price movement was “strange” given that Tesla is “very much a production ramp problem, not a demand problem.”</p>\n<p>This $100 billion market cap jump makes even less sense in the context of Tesla’s sky-high valuation before the announcement. Clearly, the feasibility of Tesla meeting the sales expectations embedded in its market cap plays no role in its valuation. For those that do care about expectations investing, I did the math and Tesla needs to successfully deliver on 155 Hertz-sized deals to meet the sales implied by a $1.2 trillion market cap.</p>\n<p><b>Will the Hertz Deal Result in Any Profits – If It Goes Through?</b></p>\n<p>After Elon Musk tweeted on November 1, 2021 that “no contract has been signed yet”, the Hertz deal reminds me of another famous tweet: \"am considering taking Tesla private at $420. Funding secured.”</p>\n<p>Even if the deal does go through, the pricing terms are very unclear. Elon insists that no cars will be sold at a discount. Meanwhile, Hertz CEO Mark Fields has made it clear that he is playing the field and working on getting cars from all EV manufacturers on his lot.</p>\n<p>Either Tesla is selling cars at a (large or small) discount, the deal terms are wrong, or the deal does not get done. If the deal gets done, I do not expect it to be profitable. Rental car companies are accustomed to getting discounts for bulk orders, and I see no reason for Hertz to expect to pay list prices on a deal for so many cars.</p>\n<p>At the end of the day, I’m not sure pricing matters because I don't think the Hertz deal gets done. This affair is more about headlines and fueling speculation than doing any real business.</p>\n<p><b>Tesla’s Global Market Share Getting Smaller</b></p>\n<p>Tesla’s first-mover is already eroding, and its market share continues to decline. In the first half of 2021, Tesla sold 14.6% of the EVs sold worldwide compared to 18.8% over the same period in 2020.</p>\n<p>Rising volumes, and falling market share are to be expected in a nascent industry. The problem is that Tesla’s isn’t priced for declining market share. It is priced for massive market share gains, unheard of gains in nearly any industry across the globe, especially in an industry as large and competitive as passenger vehicles.</p>\n<p><b>Reverse DCF Math: Valuation Implies Tesla Will Own 60%+ of the Global Passenger EV Market</b></p>\n<p>At its current average selling price (ASP) of ~$51k, Tesla’s stock price of ~1,200/share implies the firm will sell 16 million vehicles in 2030 (versus ~800k TTM), or 60% of the projected base case global EV passenger vehicle market in 2030. For reference, Adam Jonas, a Morgan Stanley analyst with a price target of $1,600/share, projects Tesla will sell 8.1 million vehicles in 2030.</p>\n<p>I think it is unlikely that Tesla will sell such a high volume of vehicles at a $51k ASP, yet the implied vehicle sales based on lower ASPs look even more impractical.</p>\n<p>As detailed in the next section, this analysis assumes Tesla achieves profit margins twice as high as Toyota (TM) and quadruples its current auto manufacturing efficiency. In other words, I aim to provide inarguably best-case scenarios for assessing the expectations reflected in Tesla’s stock price.</p>\n<p>Per Figure 3, Tesla’s current valuation implies that, in 2030, it will sell the following number of vehicles based on these ASP benchmarks:</p>\n<ul>\n <li>16 million vehicles – current ASP of $51k</li>\n <li>21 million vehicles – ASP of $38k (average new car price in the U.S. in 2020)</li>\n <li>46 million vehicles – ASP of $17k (equal to General Motors over the TTM)</li>\n</ul>\n<p>If Tesla achieves those EV sales, the implied market share for the company would be the following (assuming global passenger EV sales reach 25.8 million in 2030, the base case projection from the IEA):</p>\n<ul>\n <li>60% for 16 million vehicles</li>\n <li>80% for 21 million vehicles</li>\n <li>179% for 46 million vehicles</li>\n</ul>\n<p>If I assume the IEA’s best case for global passenger EV sales in 2030, 46.8 million vehicles, the above vehicle sales represent:</p>\n<ul>\n <li>33% for 16 million vehicles</li>\n <li>44% for 21 million vehicles</li>\n <li>98% for 46 million vehicles</li>\n</ul>\n<p><b>Figure 3: Tesla’s Implied Vehicle Sales in 2030 to Justify Current Valuation</b></p>\n<p><img src=\"https://static.tigerbbs.com/9c6d6230910209d16f55e6e527130d43\" tg-width=\"960\" tg-height=\"376\" referrerpolicy=\"no-referrer\"><b>The Math Shows that Tesla Must be More Profitable Than Apple</b></p>\n<p>Here are the assumptions I use in my reverse discounted cash flow (DCF) model to calculate the implied production levels above.</p>\n<p>To justify its current price of ~$1,200/share, Tesla must:</p>\n<ul>\n <li>immediately achieve a 17.2% NOPAT margin (double Toyota’s margin, which is the highest of the large-scale automakers I cover), compared to Tesla’s TTM margin of 7.7%) and</li>\n <li>grow revenue by 38% compounded annually for the next decade.</li>\n</ul>\n<p>In this scenario, Tesla generates <b>$783 billion</b> in revenue in 2030, which is 102% of the combined revenues of Toyota, General Motors, Ford (F), Honda Motor Corp (HMC), and Stellantis (STLA) over the TTM.</p>\n<p>This scenario also implies Tesla generates $135 billion in net operating profit after-tax (NOPAT) in 2030, or 45% higher than Apple’s (AAPL) TTM NOPAT, which, at $93 billion, is the highest of all companies my firm covers.</p>\n<p><b>TSLA Has 60%+ Downside If Morgan Stanley Is Right About Sales</b></p>\n<p>If I assume Tesla reaches Morgan Stanley’s estimate of selling 8.1 million cars in 2030 (which implies a 31% share of the global passenger EV market in 2030), at an ASP of $38k, the stock is worth just $483/share. Details:</p>\n<ul>\n <li>NOPAT margin improves to 17.2% and</li>\n <li>revenue grows 27% compounded annually over the next decade, then</li>\n</ul>\n<p>the stock is worth just $483/share today – 60% downside to the current price. See the math behind this reverse DCF scenario. In this scenario, Tesla grows NOPAT to $60 billion, or nearly 17x its TTM NOPAT, and just 3% below Alphabet’s (GOOGL) TTM NOPAT.</p>\n<p><b>TSLA Has 88%+ Downside Even with 28% Market Share and Realistic Margins</b></p>\n<p>If I estimate more reasonable (but still very optimistic) margins and market share achievements for Tesla, the stock is worth just $148/share. Here’s the math:</p>\n<ul>\n <li>NOPAT margin improves to 8.5% (equal to General Motors’ TTM margin, compared to Tesla’s TTM margin of 7.7%) and</li>\n <li>revenue grows by consensus estimates from 2021-2023 and</li>\n <li>revenue grows 18% a year from 2024-2030, then</li>\n</ul>\n<p>the stock is worth just $148/share today – an 88% downside to the current price.</p>\n<p>In this scenario, Tesla sells 7.2 million cars (at an ASP of 38k) and owns 28% of the global passenger EV market in 2030. If Tesla fails to meet these expectations, then the stock is worth less than $148/share.</p>\n<p>Also, for this scenario, I assume a much more realistic NOPAT margin, 8.5%, for Tesla. Given the expansion required of the business, struggles to be profitable to date, and formidable competition, I think Tesla will be lucky to achieve and sustain a margin as high as 8.5% from 2021-2030.</p>\n<p>Figure 4 compares the firm’s historical NOPAT to the NOPAT implied by its current stock price, the 8.1 million vehicle sales scenario, and the 7.2 million vehicle sales scenario to illustrate just how high the expectations baked into Tesla’s stock price remain. For additional context, I show Toyota’s, General Motors’, and Apple’s TTM NOPAT.</p>\n<p><b>Figure 4: Tesla’s Historical and Implied NOPAT: DCF Valuation Scenarios</b></p>\n<p><img src=\"https://static.tigerbbs.com/25d334530f3477d58879490d628fa8ef\" tg-width=\"936\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Each of the above scenarios assumes Tesla’s invested capital grows 14% compounded annually through 2030. For reference, Tesla’s invested capital grew 53% compounded annually from 2010-2020 and 29% compounded annually from 2015-2020. Invested capital at the end of 3Q21 grew 21% YoY. Tesla’s property, plant, and equipment has grown even faster, at 58% compounded annually, since 2010.</p>\n<p>A 14% CAGR represents 1/4th the CAGR of Tesla’s property, plant, and equipment since 2010 and assumes the company can build future plants and produce cars 4x more efficiently than it has so far.</p>\n<p>In other words, I aim to provide inarguably best-case scenarios for assessing the expectations for future market share and profits reflected in Tesla’s stock market valuation.</p>\n<p><b>Why Tesla’s $1 Trillion Valuation Is Ridiculous</b></p>\n<p>Now that I’ve shown how high the expectations baked into Tesla’s valuation are, I’ll present some of the many challenges Tesla faces to meet those expectations.</p>\n<p><b>Tesla Remains “Just” a Car Company, Despite Bulls’ Arguments Otherwise.</b>One of the most common arguments bulls make to justify Tesla’s valuation is that the company is more than just a car company. Instead, the argument goes: Tesla is a software, tech, insurance, energy, transportation, “insert any other blank” company. However, the financials bear out a different picture and show the other businesses are more hype than substance. At this point, Tesla is a only car company and generates the entirety of its profits from vehicles.</p>\n<p>Per Figure 5, Tesla generated 88% of revenue from Automotive Sales in 3Q21, which is up from 87% in 3Q20, and above the quarterly average of 86% since 3Q19. For reference, automotive sales made up 87% and 93% of General Motors’ and Ford’s 3Q21 revenue respectively.</p>\n<p><b>Figure 5: Tesla’s Revenue Breakdown: 3Q19 – 3Q21</b></p>\n<p><img src=\"https://static.tigerbbs.com/4b77f52dfd7a9cb05f19a91ac8811919\" tg-width=\"960\" tg-height=\"419\" referrerpolicy=\"no-referrer\">Tesla’s two other segments, Energy generation and storage and Services and other, which make up 12% of revenue in 3Q21, are unprofitable. Over the TTM, Tesla generated $10.8 billion in gross profit. $11.2 billion came from its Automotive segment while Energy generation and storage and Services and other racked up gross losses of $113 million and $263 million. Despite many claims and promises to the contrary over the years, Tesla doesn’t generate gross profit doing anything but selling cars.</p>\n<p><b>Insurance Business Is Not Material.</b> Tesla bulls will also point to Tesla’s insurance business as another way to drive profit growth. I’ve previously covered how Tesla insurance does not have the competitive advantages that bulls ascribe to it and has a long way to go before it can get meaningfully off the ground.</p>\n<p>Even if Tesla’s insurance business gets off the ground, I would not expect it to make much money. For example, from 2004-2006, General Motors generated about $70 per car sold in GAAP net income from its insurance business. If I assume Tesla can generate the same level of business, Tesla insurance would result in just $57 million in GAAP net income based on TTM vehicles sold.</p>\n<p>Bulls will counter that Tesla will be so much better at insurance than GM and that GM is not a good comp. There is no way to know for sure. Nevertheless, I concede that anything is possible, but the likelihood of Tesla’s insurance business being material profit producer is extremely low.</p>\n<p>Regardless of how successful Tesla insurance is, the potential profits from it are nowhere near enough to help to justify the expectations baked into Tesla’s stock price.</p>\n<p><b>Production Capacity Growth Will Require Billions of $.</b>Current and expected production capacities of all known Tesla factories equals ~2.7 million vehicles, or 12.9 million short of the 2030 production implied by its stock price. See Figure 6.</p>\n<p>In other words, despite the new factories coming online, Tesla must spend billions and build many new manufacturing plants before it can approach the capacity needed to sell the number of cars implied by its valuation.</p>\n<p>Given the many issues in ramping production in the past, investors should not assume Tesla can increase its production by 5x without any problems.</p>\n<p><b>Figure 6: Tesla’s Pending Production Shortfall</b></p>\n<p><img src=\"https://static.tigerbbs.com/7d0c946fecb2fd037adac367c7c5b7c2\" tg-width=\"960\" tg-height=\"285\" referrerpolicy=\"no-referrer\">*Projection based on InsideEVs estimate of 600,000 vehicles per year</p>\n<p>**Optimistic assumption based on Texas being Tesla’s biggest factory and possibly the largest factory in the United States</p>\n<p><b>Incumbents Must Fail for Tesla to Meet Growth Expectations.</b>For many years now, incumbent automakers have spent billions of dollars building out their EV offerings. Automakers other than Tesla already account for 85% of global EV sales through the first half of 2021.</p>\n<p>The global EV market is simply not big enough for Tesla to achieve the sales expectations in its valuation unless nearly all of the incumbents reverse course and completely fail to sell EVs.</p>\n<p>Here are the projections from the large incumbent automakers that have provided specific goals for future EV production.</p>\n<ul>\n <li>Volkswagen Group projects that 50% of its global sales will be fully electric by 2030</li>\n <li>Stellantis projects 70% and 40% of its European and North American sales, respectively, will be fully electric by 2030</li>\n <li>Ford projects that 40% of its sales will be fully electric by 2030.</li>\n <li>Toyota projects that it will sell 2 million EVs by 2030</li>\n <li>Honda plans to sell only EVs in China by 2030</li>\n <li>BMW expects at least half its sales to be zero-emission vehicles by 2030</li>\n <li>Daimler, manufacturer of Mercedes Benz, expects half its sales to be “EV and hybrid by 2025”</li>\n <li>General Motors is targeting EV sales of “more than 1 million” by 2025</li>\n <li>Volvo plans to sell only fully electric vehicles by 2030</li>\n <li>Nissan projects 40% of U.S. sales to be EVs by 2030</li>\n</ul>\n<p>Based on these projections, I estimate how many EVs each company aims to produce[1] by 2030 and the market share implied by that production as a percentage of base-case global passenger EV sales in 2030.</p>\n<ul>\n <li>Volkswagen Group: 5.5 million, 21% market share</li>\n <li>Stellantis: 3.6 million[2], 14% market share</li>\n <li>Ford: 2.2 million, 9% market share</li>\n <li>Toyota: 2 million, 8% market share</li>\n <li>Honda (in China): 1.5 million, 6% market share</li>\n <li>BMW: 1.3 million, 5% market share</li>\n <li>Mercedes Benz: 1.2+ million, 5% market share</li>\n <li>General Motors: 1+ million, 4% market share</li>\n <li>Volvo: 700,000, 3% market share</li>\n <li>Nissan (in U.S.): 500,000, 2% market share</li>\n <li><b>Total = 19+ million vehicles and 75% market share</b></li>\n</ul>\n<p>These estimates do not include other incumbents and new entrants (e.g. Jaguar Land Rover, NIO Inc. [NIO], Rivian [RIVN], Ludic [LCID] and more) or other Chinese EV makers because I could not find specific projections for EV production. Nevertheless, I am confident that their combined market share will be more than zero.</p>\n<p>The point is that the rest of the world is not planning to stand by, give up existing market share, and let Tesla own majority of the EV market. Many very experienced and successful automakers are spending many multiples of what Tesla is spending to compete in the EV market.</p>\n<p>The bottom line is that it is hard to make a straight-faced argument that Tesla can achieve the sales implied by its valuation in a competitive market.</p>\n<p><b>Incumbents Can Afford to Spend More than Tesla.</b>Incumbents already have infrastructure to produce and sell vehicles at scale, and they are spending billions of dollars to compete in the EV market. Ford, Volkswagen, General Motors, and Stellantis alone are planning to spend at least $280 billion through 2025 and produce over 12 million EVs by 2030.</p>\n<p>Given the huge investments from multiple competitors, I expect the EV market will be extremely competitive, as manufacturers fight for profits and market share. The “winner take all” outcome implied by Tesla’s valuation is extremely unlikely. Perhaps, Bernstein analyst Toni Sacconaghi said it best, “the automotive industry is an increasingly global and hypercompetitive industry and I believe that surplus profits and technology innovation will likely be competed away over time, as has been the case historically.\" In such a market, Tesla cannot achieve the market share implied by its valuation.</p>\n<p>Unlike Tesla, the incumbents generate plenty of free cash flow (FCF) to fund their EV investments and don’t have to dilute existing shareholders to expand EV capacity as Tesla does. For instance, over the last five years, General Motors, Stellantis, and Ford generated a cumulative $12.4 billion, $7.1, and $6.1 billion in free cash flow while Tesla burned -$19.5 billion.</p>\n<p><b>FSD Continues to Overpromise And Underdeliver.</b>Full-self driving (FSD) has been consistently plagued by issues that, unfortunately, have deadly consequences. Industry research provider Guidehouse Insights ranks Tesla last in its 2021 ranking of Automated Driver Systems (ADS), and states flatly, “Tesla needs a thorough rethink of its approach to developing ADS. It has overpromised with its marketing for nearly 5 years and severely underdelivered.”</p>\n<p>Per Figure 7, Tesla lags the competition by quite a large margin, as it’s the only company that falls into the \"Followers\" category.</p>\n<p>The most recent problems with Tesla’s FSD version 10.3 forced the company to roll back the update as users reported false crash warnings and other problems with autosteer and cruise control. These issues resulted in Tesla recalling nearly 12,000 vehicles because “a communication error may cause a false forward-collision warning or unexpected activation of the emergency brakes,” according to the National Highway Traffic Safety Administration (NHTSA).</p>\n<p>While the roll out of an updated 10.3.1 has restarted, Tesla’s haphazard approach to deploying FSD remains unsettling and led Guidehouse Insights to note, “Tesla’s approach to testing its system is fundamentally at odds with virtually every other company in this industry.”</p>\n<p><b>Figure 7: Tesla Ranks Last Amongst Automated Driver Systems</b></p>\n<p><img src=\"https://static.tigerbbs.com/6ddd92d3ed67347fa0741599f91ce31d\" tg-width=\"919\" tg-height=\"739\" width=\"100%\" height=\"auto\"></p>\n<p>Alphabet’s Waymo routinely ranks as the best automated driving system. Importantly, many of the firms ranked ahead of Tesla are focused solely on building automated driving systems and are not distracted by scaling up automobile production, delivery logistics, and the general day-to-day operations of producing cars. Even so, other direct competitors such as GM Super Cruise also get better scores from third-party organizations.</p>\n<p><b>Increased Regulatory Risk.</b>While Tesla has mysteriously avoided regulatory crackdown on its sales of FSD and practice of beta testing software on live drivers and roads, renewed requests from the NHTSA/National Transportation Safety Board (NTSB) signal that Tesla might be held accountable for practices that many find highly misleading and dangerous to citizens.</p>\n<p>Missy Cummings, recently appointed as senior advisor for safety at the NHTSA, has expressed concerns about Tesla’s FSD in the past, tweeting as far back as 2019 that Tesla’s “autopilot easily cause mode confusion, is unreliable and unsafe” and that “NHTSA should require Tesla turn it off.”</p>\n<p>More recently, Tesla requested “confidential business information treatment” on its responses to a litany of information requests the NHTSA made as part of its investigation into FSD. If approved, the public would likely never see Tesla’s responses to key questions pertaining to Tesla not issuing a recall for Autopilot after multiple accidents involving parked emergency vehicles, the selection criteria for Tesla’s FSD beta testing program, and the non-disclosure agreements Tesla was making drivers sign before they could use the beta system.</p>\n<p>The NHTSA is not alone in criticizing Tesla and its FSD rollout. On October 26, 2021, the head of the U.S. NTSB, Jennifer Homendy, said that Tesla has not yet officially responded to the NTSB regarding its safety recommendations while calling the use of full self-driving ”misleading.” She stated, “my biggest concern is that Tesla is rolling out full self-driving technology in beta on city streets with untrained drivers and they have not addressed our recommendations that we’ve issued as a result of numerous investigations of Tesla crashes.”</p>\n<p><b>Battery Technologies Are Nothing Special.</b>Tesla announced it will be switching to a lithium iron phosphate (LFP) battery in all standard range cars. These batteries are already being used in vehicles built in the Shanghai factory, and this switch is expected to bring down costs. The timing of this change comes as other battery producers, in partnership with incumbent auto manufacturers, are ramping up production, which should drive down battery costs for all EV makers. In other words, the competitive advantages of a cheaper battery may be short-lived, as incumbents build economies of scale in their own supply chain in the coming years.</p>\n<p>Additionally, while the much heralded 4680 cylindrical battery, produced by Panasonic for Tesla, and nearly ready for production, should bring a higher energy density in a more efficient package, competitors’ offerings all aim to provide the same.</p>\n<p>General Motor’s Ultium platform will enable up to 400-450 miles of range, and the firm is building a new battery research facility aimed at building batteries capable of 600 miles on a single charge. General Motors recently announced a joint venture with LG Chem to build a second U.S. battery cell plant, which is expected to have an annual capacity of 35 gigawatt hours, or slightly above the 30 gigawatt hour capacity of its first Lordstown battery plant. Morgan Stanley analyst Adam Jonas noted that the “formation of Ultium/Ultium Cells LLC will prove to be a critical point of strategic differentiation that will ultimately drive value creation for [GM] shareholders.”</p>\n<p>Ford’s Mustang Mach-E became the first electric SUV not made by Tesla to reach an EPA-rated range of up to 300 miles, and the company recently entered a partnership with SK Innovation to build three U.S.-based battery plants to power 1 million EVs annually.</p>\n<p>On its own, LG Chem plans to expand its existing U.S. facilities and build two more plants that will produce both pouch cells used by General Motors, Ford, Jaguar, Audi, Porsche, and more, as well as the cylindrical cells used by Tesla.</p>\n<p>Ultimately, the race for the “perfect” battery is less important than the race to procure battery supplies to build the number of EVs each manufacturer aims to produce in the coming years. The incumbents have proven they can maintain and win a race to procure supplies, and they’ve only been doing it for multiple decades now.</p>\n<p><b>Not All Supply Issues Can Be Coded Away.</b>To its credit, Tesla managed the global chip shortage relatively well by re-writing software to allow the use of alternative chips. However, not all supply issues can be solved via software, as evidenced by the growing wait times for Tesla’s vehicles. As Electrek notes, Tesla recently updated its delivery timelines for new orders, and depending upon specs, some vehicles won’t be delivered until September 2022 if ordered today. New orders for the Model 3 Standard Range Plus, which is Tesla’s cheapest vehicle, are currently on pace to be delivered in May 2022, or seven months from now.</p>\n<p>While certainly not unique to Tesla, extended delivery/wait times give consumers ample time to comparison shop and possibly switch orders to a competitor’s EV that would be available sooner.</p>\n<p>Delivery delays aren’t exclusive to in-production vehicles, but Tesla’s future vehicles as well. The much-hyped Cybertruck has recently been delayed again, this time until at least 2023 (compared to an original late 2021 release), which ultimately gives competitors more time to establish a presence in the EV truck market. I recently outlined the many competitors in the EV truck market in my report on Rivian.</p>\n<p><b>Putting It All Together: Tesla Provides Poor Risk/Reward</b></p>\n<p>Given the challenges ahead for Tesla, coupled with a valuation that implies it will take 60%+ of the global EV market share, I think it is clear: Tesla’s stock offers poor risk/reward.</p>\n<p>Tesla has proven risky to short, but investors need not buy shares today at such an elevated price.</p>\n<p>If you’re buying Tesla at its current valuation, you’re not only betting that it will be the only winner of the electrification of the global automotive fleet, but that it will somehow be twice as profitable as Toyota and achieve at least 60% market share. With anything less than total market domination, TSLA presents large downside risk.</p>","source":"fors","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla: $1 Trillion Of Speculation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla: $1 Trillion Of Speculation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 22:10 GMT+8 <a href=https://www.forbes.com/sites/greatspeculations/2021/11/09/tesla-1-trillion-of-speculation/?sh=34ca1f2f77eb><strong>Forbes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla’s (TSLA) market cap surpassed the trillion-dollar mark, driven by a post-earnings rally that got a boost from the announcement of a 100,000-vehicle order from Hertz (HTZ), which might not even ...</p>\n\n<a href=\"https://www.forbes.com/sites/greatspeculations/2021/11/09/tesla-1-trillion-of-speculation/?sh=34ca1f2f77eb\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.forbes.com/sites/greatspeculations/2021/11/09/tesla-1-trillion-of-speculation/?sh=34ca1f2f77eb","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163118124","content_text":"Tesla’s (TSLA) market cap surpassed the trillion-dollar mark, driven by a post-earnings rally that got a boost from the announcement of a 100,000-vehicle order from Hertz (HTZ), which might not even happen.\nEven if it does come to pass, the Hertz order is a drop in the bucket of growth expectations baked into Tesla’s valuation. Tesla needs 155 Hertz-sized orders to justify the revenue expectations in its stock price. Put another way, the $1.2 trillion valuation implies Tesla owns 60%+ of the entire global passenger EV market and becomes more profitable than Apple (AAPL) by 2030.\nThis report provides objective perspective on how outrageously high the valuation of Tesla stock is and the clear impracticality of the company meeting the expectations baked into its valuation.\nTesla’s Valuation vs. Competitors Makes No Sense\nTesla’s market cap is now greater than the next 10 largest (ranked by market cap) auto manufacturers combined.\nFigure 1: Tesla’s Market Cap Vs. Competitors\n\nThis valuation comes despite Tesla selling less than 1/50th of the vehicles than the combined total sold by the next 10 largest automakers over the trailing twelve months ended the first half of 2021. See Figure 2.\nI cannot conceive of a straight-faced argument for the disconnect between Tesla’s valuation and its vehicle sales compared to its competitors.\nFigure 2: Tesla’s Car Sales Vs. Competitors\n* Stellantis sales estimated as Fiat Chrysler and PSA Group’s 2H20 sales and Stellantis’ 1H21 sales. Stellantis was formed as a merger between the two in January 2021.\nIs the Hertz Deal Really Worth $100 Billion+ in Market Cap?\nEven if Hertz eventually agrees to buy 100,000 Tesla Model 3s, I do not think it is worth the $100 billion in market cap, or $1 million per vehicle, that we saw investors give Tesla’s market cap after the Hertz deal made headlines. Even Elon Musk questioned the surge in share price, noting that the price movement was “strange” given that Tesla is “very much a production ramp problem, not a demand problem.”\nThis $100 billion market cap jump makes even less sense in the context of Tesla’s sky-high valuation before the announcement. Clearly, the feasibility of Tesla meeting the sales expectations embedded in its market cap plays no role in its valuation. For those that do care about expectations investing, I did the math and Tesla needs to successfully deliver on 155 Hertz-sized deals to meet the sales implied by a $1.2 trillion market cap.\nWill the Hertz Deal Result in Any Profits – If It Goes Through?\nAfter Elon Musk tweeted on November 1, 2021 that “no contract has been signed yet”, the Hertz deal reminds me of another famous tweet: \"am considering taking Tesla private at $420. Funding secured.”\nEven if the deal does go through, the pricing terms are very unclear. Elon insists that no cars will be sold at a discount. Meanwhile, Hertz CEO Mark Fields has made it clear that he is playing the field and working on getting cars from all EV manufacturers on his lot.\nEither Tesla is selling cars at a (large or small) discount, the deal terms are wrong, or the deal does not get done. If the deal gets done, I do not expect it to be profitable. Rental car companies are accustomed to getting discounts for bulk orders, and I see no reason for Hertz to expect to pay list prices on a deal for so many cars.\nAt the end of the day, I’m not sure pricing matters because I don't think the Hertz deal gets done. This affair is more about headlines and fueling speculation than doing any real business.\nTesla’s Global Market Share Getting Smaller\nTesla’s first-mover is already eroding, and its market share continues to decline. In the first half of 2021, Tesla sold 14.6% of the EVs sold worldwide compared to 18.8% over the same period in 2020.\nRising volumes, and falling market share are to be expected in a nascent industry. The problem is that Tesla’s isn’t priced for declining market share. It is priced for massive market share gains, unheard of gains in nearly any industry across the globe, especially in an industry as large and competitive as passenger vehicles.\nReverse DCF Math: Valuation Implies Tesla Will Own 60%+ of the Global Passenger EV Market\nAt its current average selling price (ASP) of ~$51k, Tesla’s stock price of ~1,200/share implies the firm will sell 16 million vehicles in 2030 (versus ~800k TTM), or 60% of the projected base case global EV passenger vehicle market in 2030. For reference, Adam Jonas, a Morgan Stanley analyst with a price target of $1,600/share, projects Tesla will sell 8.1 million vehicles in 2030.\nI think it is unlikely that Tesla will sell such a high volume of vehicles at a $51k ASP, yet the implied vehicle sales based on lower ASPs look even more impractical.\nAs detailed in the next section, this analysis assumes Tesla achieves profit margins twice as high as Toyota (TM) and quadruples its current auto manufacturing efficiency. In other words, I aim to provide inarguably best-case scenarios for assessing the expectations reflected in Tesla’s stock price.\nPer Figure 3, Tesla’s current valuation implies that, in 2030, it will sell the following number of vehicles based on these ASP benchmarks:\n\n16 million vehicles – current ASP of $51k\n21 million vehicles – ASP of $38k (average new car price in the U.S. in 2020)\n46 million vehicles – ASP of $17k (equal to General Motors over the TTM)\n\nIf Tesla achieves those EV sales, the implied market share for the company would be the following (assuming global passenger EV sales reach 25.8 million in 2030, the base case projection from the IEA):\n\n60% for 16 million vehicles\n80% for 21 million vehicles\n179% for 46 million vehicles\n\nIf I assume the IEA’s best case for global passenger EV sales in 2030, 46.8 million vehicles, the above vehicle sales represent:\n\n33% for 16 million vehicles\n44% for 21 million vehicles\n98% for 46 million vehicles\n\nFigure 3: Tesla’s Implied Vehicle Sales in 2030 to Justify Current Valuation\nThe Math Shows that Tesla Must be More Profitable Than Apple\nHere are the assumptions I use in my reverse discounted cash flow (DCF) model to calculate the implied production levels above.\nTo justify its current price of ~$1,200/share, Tesla must:\n\nimmediately achieve a 17.2% NOPAT margin (double Toyota’s margin, which is the highest of the large-scale automakers I cover), compared to Tesla’s TTM margin of 7.7%) and\ngrow revenue by 38% compounded annually for the next decade.\n\nIn this scenario, Tesla generates $783 billion in revenue in 2030, which is 102% of the combined revenues of Toyota, General Motors, Ford (F), Honda Motor Corp (HMC), and Stellantis (STLA) over the TTM.\nThis scenario also implies Tesla generates $135 billion in net operating profit after-tax (NOPAT) in 2030, or 45% higher than Apple’s (AAPL) TTM NOPAT, which, at $93 billion, is the highest of all companies my firm covers.\nTSLA Has 60%+ Downside If Morgan Stanley Is Right About Sales\nIf I assume Tesla reaches Morgan Stanley’s estimate of selling 8.1 million cars in 2030 (which implies a 31% share of the global passenger EV market in 2030), at an ASP of $38k, the stock is worth just $483/share. Details:\n\nNOPAT margin improves to 17.2% and\nrevenue grows 27% compounded annually over the next decade, then\n\nthe stock is worth just $483/share today – 60% downside to the current price. See the math behind this reverse DCF scenario. In this scenario, Tesla grows NOPAT to $60 billion, or nearly 17x its TTM NOPAT, and just 3% below Alphabet’s (GOOGL) TTM NOPAT.\nTSLA Has 88%+ Downside Even with 28% Market Share and Realistic Margins\nIf I estimate more reasonable (but still very optimistic) margins and market share achievements for Tesla, the stock is worth just $148/share. Here’s the math:\n\nNOPAT margin improves to 8.5% (equal to General Motors’ TTM margin, compared to Tesla’s TTM margin of 7.7%) and\nrevenue grows by consensus estimates from 2021-2023 and\nrevenue grows 18% a year from 2024-2030, then\n\nthe stock is worth just $148/share today – an 88% downside to the current price.\nIn this scenario, Tesla sells 7.2 million cars (at an ASP of 38k) and owns 28% of the global passenger EV market in 2030. If Tesla fails to meet these expectations, then the stock is worth less than $148/share.\nAlso, for this scenario, I assume a much more realistic NOPAT margin, 8.5%, for Tesla. Given the expansion required of the business, struggles to be profitable to date, and formidable competition, I think Tesla will be lucky to achieve and sustain a margin as high as 8.5% from 2021-2030.\nFigure 4 compares the firm’s historical NOPAT to the NOPAT implied by its current stock price, the 8.1 million vehicle sales scenario, and the 7.2 million vehicle sales scenario to illustrate just how high the expectations baked into Tesla’s stock price remain. For additional context, I show Toyota’s, General Motors’, and Apple’s TTM NOPAT.\nFigure 4: Tesla’s Historical and Implied NOPAT: DCF Valuation Scenarios\n\nEach of the above scenarios assumes Tesla’s invested capital grows 14% compounded annually through 2030. For reference, Tesla’s invested capital grew 53% compounded annually from 2010-2020 and 29% compounded annually from 2015-2020. Invested capital at the end of 3Q21 grew 21% YoY. Tesla’s property, plant, and equipment has grown even faster, at 58% compounded annually, since 2010.\nA 14% CAGR represents 1/4th the CAGR of Tesla’s property, plant, and equipment since 2010 and assumes the company can build future plants and produce cars 4x more efficiently than it has so far.\nIn other words, I aim to provide inarguably best-case scenarios for assessing the expectations for future market share and profits reflected in Tesla’s stock market valuation.\nWhy Tesla’s $1 Trillion Valuation Is Ridiculous\nNow that I’ve shown how high the expectations baked into Tesla’s valuation are, I’ll present some of the many challenges Tesla faces to meet those expectations.\nTesla Remains “Just” a Car Company, Despite Bulls’ Arguments Otherwise.One of the most common arguments bulls make to justify Tesla’s valuation is that the company is more than just a car company. Instead, the argument goes: Tesla is a software, tech, insurance, energy, transportation, “insert any other blank” company. However, the financials bear out a different picture and show the other businesses are more hype than substance. At this point, Tesla is a only car company and generates the entirety of its profits from vehicles.\nPer Figure 5, Tesla generated 88% of revenue from Automotive Sales in 3Q21, which is up from 87% in 3Q20, and above the quarterly average of 86% since 3Q19. For reference, automotive sales made up 87% and 93% of General Motors’ and Ford’s 3Q21 revenue respectively.\nFigure 5: Tesla’s Revenue Breakdown: 3Q19 – 3Q21\nTesla’s two other segments, Energy generation and storage and Services and other, which make up 12% of revenue in 3Q21, are unprofitable. Over the TTM, Tesla generated $10.8 billion in gross profit. $11.2 billion came from its Automotive segment while Energy generation and storage and Services and other racked up gross losses of $113 million and $263 million. Despite many claims and promises to the contrary over the years, Tesla doesn’t generate gross profit doing anything but selling cars.\nInsurance Business Is Not Material. Tesla bulls will also point to Tesla’s insurance business as another way to drive profit growth. I’ve previously covered how Tesla insurance does not have the competitive advantages that bulls ascribe to it and has a long way to go before it can get meaningfully off the ground.\nEven if Tesla’s insurance business gets off the ground, I would not expect it to make much money. For example, from 2004-2006, General Motors generated about $70 per car sold in GAAP net income from its insurance business. If I assume Tesla can generate the same level of business, Tesla insurance would result in just $57 million in GAAP net income based on TTM vehicles sold.\nBulls will counter that Tesla will be so much better at insurance than GM and that GM is not a good comp. There is no way to know for sure. Nevertheless, I concede that anything is possible, but the likelihood of Tesla’s insurance business being material profit producer is extremely low.\nRegardless of how successful Tesla insurance is, the potential profits from it are nowhere near enough to help to justify the expectations baked into Tesla’s stock price.\nProduction Capacity Growth Will Require Billions of $.Current and expected production capacities of all known Tesla factories equals ~2.7 million vehicles, or 12.9 million short of the 2030 production implied by its stock price. See Figure 6.\nIn other words, despite the new factories coming online, Tesla must spend billions and build many new manufacturing plants before it can approach the capacity needed to sell the number of cars implied by its valuation.\nGiven the many issues in ramping production in the past, investors should not assume Tesla can increase its production by 5x without any problems.\nFigure 6: Tesla’s Pending Production Shortfall\n*Projection based on InsideEVs estimate of 600,000 vehicles per year\n**Optimistic assumption based on Texas being Tesla’s biggest factory and possibly the largest factory in the United States\nIncumbents Must Fail for Tesla to Meet Growth Expectations.For many years now, incumbent automakers have spent billions of dollars building out their EV offerings. Automakers other than Tesla already account for 85% of global EV sales through the first half of 2021.\nThe global EV market is simply not big enough for Tesla to achieve the sales expectations in its valuation unless nearly all of the incumbents reverse course and completely fail to sell EVs.\nHere are the projections from the large incumbent automakers that have provided specific goals for future EV production.\n\nVolkswagen Group projects that 50% of its global sales will be fully electric by 2030\nStellantis projects 70% and 40% of its European and North American sales, respectively, will be fully electric by 2030\nFord projects that 40% of its sales will be fully electric by 2030.\nToyota projects that it will sell 2 million EVs by 2030\nHonda plans to sell only EVs in China by 2030\nBMW expects at least half its sales to be zero-emission vehicles by 2030\nDaimler, manufacturer of Mercedes Benz, expects half its sales to be “EV and hybrid by 2025”\nGeneral Motors is targeting EV sales of “more than 1 million” by 2025\nVolvo plans to sell only fully electric vehicles by 2030\nNissan projects 40% of U.S. sales to be EVs by 2030\n\nBased on these projections, I estimate how many EVs each company aims to produce[1] by 2030 and the market share implied by that production as a percentage of base-case global passenger EV sales in 2030.\n\nVolkswagen Group: 5.5 million, 21% market share\nStellantis: 3.6 million[2], 14% market share\nFord: 2.2 million, 9% market share\nToyota: 2 million, 8% market share\nHonda (in China): 1.5 million, 6% market share\nBMW: 1.3 million, 5% market share\nMercedes Benz: 1.2+ million, 5% market share\nGeneral Motors: 1+ million, 4% market share\nVolvo: 700,000, 3% market share\nNissan (in U.S.): 500,000, 2% market share\nTotal = 19+ million vehicles and 75% market share\n\nThese estimates do not include other incumbents and new entrants (e.g. Jaguar Land Rover, NIO Inc. [NIO], Rivian [RIVN], Ludic [LCID] and more) or other Chinese EV makers because I could not find specific projections for EV production. Nevertheless, I am confident that their combined market share will be more than zero.\nThe point is that the rest of the world is not planning to stand by, give up existing market share, and let Tesla own majority of the EV market. Many very experienced and successful automakers are spending many multiples of what Tesla is spending to compete in the EV market.\nThe bottom line is that it is hard to make a straight-faced argument that Tesla can achieve the sales implied by its valuation in a competitive market.\nIncumbents Can Afford to Spend More than Tesla.Incumbents already have infrastructure to produce and sell vehicles at scale, and they are spending billions of dollars to compete in the EV market. Ford, Volkswagen, General Motors, and Stellantis alone are planning to spend at least $280 billion through 2025 and produce over 12 million EVs by 2030.\nGiven the huge investments from multiple competitors, I expect the EV market will be extremely competitive, as manufacturers fight for profits and market share. The “winner take all” outcome implied by Tesla’s valuation is extremely unlikely. Perhaps, Bernstein analyst Toni Sacconaghi said it best, “the automotive industry is an increasingly global and hypercompetitive industry and I believe that surplus profits and technology innovation will likely be competed away over time, as has been the case historically.\" In such a market, Tesla cannot achieve the market share implied by its valuation.\nUnlike Tesla, the incumbents generate plenty of free cash flow (FCF) to fund their EV investments and don’t have to dilute existing shareholders to expand EV capacity as Tesla does. For instance, over the last five years, General Motors, Stellantis, and Ford generated a cumulative $12.4 billion, $7.1, and $6.1 billion in free cash flow while Tesla burned -$19.5 billion.\nFSD Continues to Overpromise And Underdeliver.Full-self driving (FSD) has been consistently plagued by issues that, unfortunately, have deadly consequences. Industry research provider Guidehouse Insights ranks Tesla last in its 2021 ranking of Automated Driver Systems (ADS), and states flatly, “Tesla needs a thorough rethink of its approach to developing ADS. It has overpromised with its marketing for nearly 5 years and severely underdelivered.”\nPer Figure 7, Tesla lags the competition by quite a large margin, as it’s the only company that falls into the \"Followers\" category.\nThe most recent problems with Tesla’s FSD version 10.3 forced the company to roll back the update as users reported false crash warnings and other problems with autosteer and cruise control. These issues resulted in Tesla recalling nearly 12,000 vehicles because “a communication error may cause a false forward-collision warning or unexpected activation of the emergency brakes,” according to the National Highway Traffic Safety Administration (NHTSA).\nWhile the roll out of an updated 10.3.1 has restarted, Tesla’s haphazard approach to deploying FSD remains unsettling and led Guidehouse Insights to note, “Tesla’s approach to testing its system is fundamentally at odds with virtually every other company in this industry.”\nFigure 7: Tesla Ranks Last Amongst Automated Driver Systems\n\nAlphabet’s Waymo routinely ranks as the best automated driving system. Importantly, many of the firms ranked ahead of Tesla are focused solely on building automated driving systems and are not distracted by scaling up automobile production, delivery logistics, and the general day-to-day operations of producing cars. Even so, other direct competitors such as GM Super Cruise also get better scores from third-party organizations.\nIncreased Regulatory Risk.While Tesla has mysteriously avoided regulatory crackdown on its sales of FSD and practice of beta testing software on live drivers and roads, renewed requests from the NHTSA/National Transportation Safety Board (NTSB) signal that Tesla might be held accountable for practices that many find highly misleading and dangerous to citizens.\nMissy Cummings, recently appointed as senior advisor for safety at the NHTSA, has expressed concerns about Tesla’s FSD in the past, tweeting as far back as 2019 that Tesla’s “autopilot easily cause mode confusion, is unreliable and unsafe” and that “NHTSA should require Tesla turn it off.”\nMore recently, Tesla requested “confidential business information treatment” on its responses to a litany of information requests the NHTSA made as part of its investigation into FSD. If approved, the public would likely never see Tesla’s responses to key questions pertaining to Tesla not issuing a recall for Autopilot after multiple accidents involving parked emergency vehicles, the selection criteria for Tesla’s FSD beta testing program, and the non-disclosure agreements Tesla was making drivers sign before they could use the beta system.\nThe NHTSA is not alone in criticizing Tesla and its FSD rollout. On October 26, 2021, the head of the U.S. NTSB, Jennifer Homendy, said that Tesla has not yet officially responded to the NTSB regarding its safety recommendations while calling the use of full self-driving ”misleading.” She stated, “my biggest concern is that Tesla is rolling out full self-driving technology in beta on city streets with untrained drivers and they have not addressed our recommendations that we’ve issued as a result of numerous investigations of Tesla crashes.”\nBattery Technologies Are Nothing Special.Tesla announced it will be switching to a lithium iron phosphate (LFP) battery in all standard range cars. These batteries are already being used in vehicles built in the Shanghai factory, and this switch is expected to bring down costs. The timing of this change comes as other battery producers, in partnership with incumbent auto manufacturers, are ramping up production, which should drive down battery costs for all EV makers. In other words, the competitive advantages of a cheaper battery may be short-lived, as incumbents build economies of scale in their own supply chain in the coming years.\nAdditionally, while the much heralded 4680 cylindrical battery, produced by Panasonic for Tesla, and nearly ready for production, should bring a higher energy density in a more efficient package, competitors’ offerings all aim to provide the same.\nGeneral Motor’s Ultium platform will enable up to 400-450 miles of range, and the firm is building a new battery research facility aimed at building batteries capable of 600 miles on a single charge. General Motors recently announced a joint venture with LG Chem to build a second U.S. battery cell plant, which is expected to have an annual capacity of 35 gigawatt hours, or slightly above the 30 gigawatt hour capacity of its first Lordstown battery plant. Morgan Stanley analyst Adam Jonas noted that the “formation of Ultium/Ultium Cells LLC will prove to be a critical point of strategic differentiation that will ultimately drive value creation for [GM] shareholders.”\nFord’s Mustang Mach-E became the first electric SUV not made by Tesla to reach an EPA-rated range of up to 300 miles, and the company recently entered a partnership with SK Innovation to build three U.S.-based battery plants to power 1 million EVs annually.\nOn its own, LG Chem plans to expand its existing U.S. facilities and build two more plants that will produce both pouch cells used by General Motors, Ford, Jaguar, Audi, Porsche, and more, as well as the cylindrical cells used by Tesla.\nUltimately, the race for the “perfect” battery is less important than the race to procure battery supplies to build the number of EVs each manufacturer aims to produce in the coming years. The incumbents have proven they can maintain and win a race to procure supplies, and they’ve only been doing it for multiple decades now.\nNot All Supply Issues Can Be Coded Away.To its credit, Tesla managed the global chip shortage relatively well by re-writing software to allow the use of alternative chips. However, not all supply issues can be solved via software, as evidenced by the growing wait times for Tesla’s vehicles. As Electrek notes, Tesla recently updated its delivery timelines for new orders, and depending upon specs, some vehicles won’t be delivered until September 2022 if ordered today. New orders for the Model 3 Standard Range Plus, which is Tesla’s cheapest vehicle, are currently on pace to be delivered in May 2022, or seven months from now.\nWhile certainly not unique to Tesla, extended delivery/wait times give consumers ample time to comparison shop and possibly switch orders to a competitor’s EV that would be available sooner.\nDelivery delays aren’t exclusive to in-production vehicles, but Tesla’s future vehicles as well. The much-hyped Cybertruck has recently been delayed again, this time until at least 2023 (compared to an original late 2021 release), which ultimately gives competitors more time to establish a presence in the EV truck market. I recently outlined the many competitors in the EV truck market in my report on Rivian.\nPutting It All Together: Tesla Provides Poor Risk/Reward\nGiven the challenges ahead for Tesla, coupled with a valuation that implies it will take 60%+ of the global EV market share, I think it is clear: Tesla’s stock offers poor risk/reward.\nTesla has proven risky to short, but investors need not buy shares today at such an elevated price.\nIf you’re buying Tesla at its current valuation, you’re not only betting that it will be the only winner of the electrification of the global automotive fleet, but that it will somehow be twice as profitable as Toyota and achieve at least 60% market share. With anything less than total market domination, TSLA presents large downside risk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":795,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":603919337,"gmtCreate":1638350710918,"gmtModify":1638350710990,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Huatz ","listText":"Huatz ","text":"Huatz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603919337","repostId":"1116877933","repostType":2,"repost":{"id":"1116877933","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638350081,"share":"https://www.laohu8.com/m/news/1116877933?lang=&edition=full","pubTime":"2021-12-01 17:14","market":"us","language":"en","title":"Merck shares jumped 5.3% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1116877933","media":"Tiger Newspress","summary":"Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close","content":"<p>Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.</p>\n<p><img src=\"https://static.tigerbbs.com/52b0f147fff1ac74d32cd5d5643fe2b3\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>The Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>The company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.</p>\n<p>Members of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.</p>\n<p>\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"</p>\n<p>Some Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.</p>\n<p>\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.</p>\n<p>Of the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.</p>\n<p>The monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.</p>\n<p>Molnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.</p>\n<p>Wall Street's interest in Merck's pill began to wane in November when Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.</p>\n<p>Then, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.</p>\n<p>\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.</p>\n<p>Analysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.</p>\n<p>Citi on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.</p>\n<p>Merck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.</p>\n<p>The Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.</p>\n<p>Molnupiravir has already been authorized for use in the U.K.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck shares jumped 5.3% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck shares jumped 5.3% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.</p>\n<p><img src=\"https://static.tigerbbs.com/52b0f147fff1ac74d32cd5d5643fe2b3\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>The Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>The company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.</p>\n<p>Members of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.</p>\n<p>\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"</p>\n<p>Some Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.</p>\n<p>\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.</p>\n<p>Of the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.</p>\n<p>The monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.</p>\n<p>Molnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.</p>\n<p>Wall Street's interest in Merck's pill began to wane in November when Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.</p>\n<p>Then, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.</p>\n<p>\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.</p>\n<p>Analysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.</p>\n<p>Citi on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.</p>\n<p>Merck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.</p>\n<p>The Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.</p>\n<p>Molnupiravir has already been authorized for use in the U.K.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116877933","content_text":"Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.\n\nThe Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.\nThe company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.\nThe FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.\nIf molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.\nMembers of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.\n\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"\nSome Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.\n\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.\nOf the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.\nThe monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.\nMolnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.\nWall Street's interest in Merck's pill began to wane in November when Pfizer Inc. $(PFE)$ produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.\nThen, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.\n\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.\nAnalysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.\nCiti on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.\nMerck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.\nThe Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.\nMolnupiravir has already been authorized for use in the U.K.","news_type":1},"isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879574401,"gmtCreate":1636758992535,"gmtModify":1636758992535,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879574401","repostId":"1163118124","repostType":4,"isVote":1,"tweetType":1,"viewCount":795,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607649897,"gmtCreate":1639536362062,"gmtModify":1639536362062,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607649897","repostId":"1180160205","repostType":4,"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
